Pfizer CFO said on an earnings call with analysts that his company is looking for acquisitions worth between a few billion to several billion dollars.
Continued here:
Genzyme and Pfizer, Kissin’ in a Tree? Probably Not.
Also: a new head for PhRMA; Maine wants out, temporarily, of one health-overhaul requirement; a union’s suit against Pfizer.
Read this article:
A.M. Vitals: Avandia Meeting, Day One: ‘Garbage’ Data and Court Settlements
Pfizer, Roche, Eli Lilly and Bristol Myers-Squibb were among the companies with data out this weekend.
More here:
What Happened at ASCO Over the Weekend
Pfizer dominated the samples biz, with $2.7 billion in free meds in 2007.
Visit link:
Big Drug Companies Gave Out $3 Billion in Samples in ‘07
The reductions fall under Pfizer’s previously announced intention to eventually eliminate 19,000 positions.
Here is the original post:
Pfizer Will Cut 6,000 Jobs as Part of Wyeth Consolidation
Merck today highlighted cardiovascular pipeline with six molecules in late-stage development. Among them: anacetrapib — a molecular cousin to a drug Pfizer once had in development.
Read the original post:
Merck To Move Ahead on a Heart Drug Where Pfizer Failed
We can fill in the another line on that always-popular list — Where Are the Ex-Pharma CEOs Now? This time, the career move involves Bob Essner, who was CEO of Wyeth between 2001 and the end of 2007 and retired a few months later as chairman of Wyeth (now part of Pfizer) at age 60
Originally posted here:
Ex-Wyeth CEO Bob Essner Moves to Private Equity’s Carlyle Group
Today in London the FDA decided to postpone approval of a new experimental heart drug, seeking more information about the new product. The drug called Certriad, combines AstraZeneca’s blockbuster cholesterol pill Crestor with Abbott Laboratories TriLipix .
The world’s biggest generic drug maker is getting bigger with the announcement this morning that Israel’s Teva Pharmaceutical had won the bidding against Pfizer for Germany’s Ratiopharm Group. The pricetag: $4.97 billlion.
Originally posted here:
Teva Outwrestles Pfizer to Land Generics Maker Ratiopharm
Bad news on the Alzheimer’s drug development front: Pfizer and Medivation announced negative results from a large late-stage trial of Dimebon, thought to be a promising treatment more potent than those currently on the market. Dimebon, you may remember, got its start a quarter-century ago as a Russian cold medicine that Pfizer plunked down $225 million for licensing rights in 2008
Read more:
Pfizer-Backed Experimental Drug for Alzheimer’s Fails in Trial
